This study was conducted to analyze and elucidate key prognostic factors for gastric cancer (GC), and to understand the current status of GC diagnosis and treatment in Hubei Province, China. Major clinical and pathological information on 154 GC patients was retrospectively collected, including gender, age, tumor site, surgical approach, histological type, TNM stage and chemotherapy cycles. Overall survival (OS) was analyzed in relation to these factors. The median OS was 12.0 months (0.5-69.0 months), and 1-, 2-, 3- and 5-year survival rates were 53.0%, 23.0%, 8.0% and 1.0%, respectively. The median OS by TNM stage was 21.0 months for stages I+II and 11.5 months in stages III+IV (P=0.043), and 1-, 2-, 3- and 5-year survival rates were 72.0% vs 50.0%, 40.0% vs 19.0%, 16.0% vs 6.0% and 0% vs 1.0 %, respectively. The median OS by chemotherapy cycles was 18.0 months in chemotherapy ≥6 cycles group and 11.0 months in chemotherapy <6 cycles group (P=0.009), and 1-, 2-, 3- and 5-year survival rates were 68.0% vs 49.0%, 41.0% vs 18.0%, 12.0% vs 7.0% and 0% vs 1.0%, respectively. Multivariate analysis identified tumor site, surgical approach and chemotherapy cycles as independent predictors for improved survival. Implementation of standardized radical surgery and reasonable adjuvant therapy could improve survival and prognosis of GC patients.